Smoking status as a potential confound in the BOLD response of patients with schizophrenia

Schizophrenia Research

Volumn 104, Issue 1-3, 2008, Pages 79-84

  Leyba, Leonard ^a,b   Mayer, Andrew R ^a,c   Gollub, Randy L ^a,d   Andreasen, Nancy C ^a,e   Clark, Vincent P ^a,b,f  

^a MIND RESEARCH NETWORK   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Atherosclerosis; Cigarette; Functional magnetic resonance imaging; Nicotine; Schizophrenia; Vascular disease

Indexed keywords

OXYGEN;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; MENTAL PATIENT; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION;

ADULT; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; PREVALENCE; PSYCHOMOTOR DISORDERS; SCHIZOPHRENIA; SMOKING; YOUNG ADULT;

EID: 50249087998     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.06.008     Document Type: Article

References (49)

1. Aguirre G.K., and D'Esposito M. Experimental design for brain FMRI. In: Moonen C.T.W., and Bandettini P.A. (Eds). Functional MRI (2000), Springer-Verlag, Berlin 371
2. Aitchison R., and Russell N. Smoking-a major cause of polycythaemia. J. R. Soc. Med. 81 (1988) 89-91
3. Bandettini P.A., and Wong E.C. A hypercapnia-based normalization method for improved spatial localization of human brain activation with fMRI. NMR Biomed. 10 (1997) 197-203
4. Barch D.M., Mathews J.R., Buckner R.L., Maccotta L., Csernansky J.G., and Snyder A.Z. Hemodynamic responses in visual, motor, and somatosensory cortices in schizophrenia. Neuroimage 20 (2003) 1884-1893
5. Braus D.F., Weber-Fahr W., Tost H., Ruf M., and Henn F.A. Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study. Arch. Gen. Psychiatry 59 (2002) 696-701
6. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., Marks M.J., Collins A.C., and Leonard S. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23 (2000) 351-364
7. Buxton R.B. Introduction to Functional Magnetic Resonance Imaging (2003), Cambridge University Press, Cambridge, United Kingdom
8. Callicott J.H. An expanded role for functional neuroimaging in schizophrenia. Curr. Opin. Neurobiol. 13 (2003) 256-260
9. Cohen E.R., Rostrup E., Sidaros K., Lund T.E., Paulson O.B., Ugurbil K., and Kim S.G. Hypercapnic normalization of BOLD fMRI: comparison across field strengths and pulse sequences. Neuroimage 23 (2004) 613-624
10. Cohen M.S. Parametric analysis of fMRI data using linear systems methods. Neuroimage 6 (1997) 93-103
11. Cox R.W. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res. 29 (1996) 162-173
12. D'Esposito M., Deouell L.Y., and Gazzaley A. Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. Nat. Rev. Neurosci. 4 (2003) 863-872
13. Davis C.E., Jeste D.V., and Eyler L.T. Review of longitudinal functional neuroimaging studies of drug treatments in patients with schizophrenia. Schizophr. Res. 78 (2005) 45-60
14. Forman S.D., Cohen J.D., Fitzgerald M., Eddy W.F., Mintun M.A., and Noll D.C. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn. Reson. Med. 33 (1995) 636-647
15. Friedman L., Stern H., Brown G.G., Mathalon D.H., Turner J., Glover G.H., Gollub R.L., Lauriello J., Lim K.O., Cannon T., Greve D.N., Bockholt H.J., Belger A., Mueller B., Doty M.J., He J., Wells W., Smyth P., Pieper S., Kim S., Kubicki M., Vangel M., and Potkin S.G. Test-retest and between-site reliability in a multicenter fMRI study. Hum. Brain Mapp. 29 8 (2008) 958-972
16. Friedman L., Turner J.A., Stern H., Mathalon D.H., Trondsen L.C., and Potkin S.G. Chronic smoking and the BOLD response to a visual activation task and a breath hold task in patients with schizophrenia and healthy controls. Neuroimage 40 (2008) 1181-1194
17. Gentry C.L., and Lukas R.J. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 359-385
18. Goff, D.C., Cather, C., Evins, A.E., Henderson, D.C., Freudenreich, O., Copeland, P.M., Bierer, M., Duckworth, K., Sacks, F.M., 2005. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatry 66, 183-194; Quiz 147, 273-184.
19. Gustard S., Williams E.J., Hall L.D., Pickard J.D., and Carpenter T.A. Influence of baseline hematocrit on between-subject BOLD signal change using gradient echo and asymmetric spin echo EPI. Magn. Reson. Imaging 21 (2003) 599-607
20. Hahn B., Ross T.J., Yang Y., Kim I., Huestis M.A., and Stein E.A. Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J. Neurosci. 27 (2007) 3477-3489
21. Hanna S.T. Nicotine effect on cardiovascular system and ion channels. J. Cardiovasc. Pharmacol. 47 (2006) 348-358
22. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
23. Ingall T.J., Homer D., Baker Jr. H.L., Kottke B.A., O'Fallon W.M., and Whisnant J.P. Predictors of intracranial carotid artery atherosclerosis. Duration of cigarette smoking and hypertension are more powerful than serum lipid levels. Arch. Neurol. 48 (1991) 687-691
24. Isaka Y., Ashida K., Imaizumi M., and Abe H. Effect of chronic smoking on regional cerebral blood flow in asymptomatic individuals. Yakubutsu Seishin Kodo 13 (1993) 191-198
25. Jacobsen L.K., Gore J.C., Skudlarski P., Lacadie C.M., Jatlow P., and Krystal J.H. Impact of intravenous nicotine on BOLD signal response to photic stimulation. Magn. Reson. Imaging 20 (2002) 141-145
26. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry 64 Suppl 12 (2003) 5-19
27. Kircher T.T., and Thienel R. Functional brain imaging of symptoms and cognition in schizophrenia. Prog. Brain Res. 150 (2005) 299-308
28. Kubota K., Yamaguchi T., Abe Y., Fujiwara T., Hatazawa J., and Matsuzawa T. Effects of smoking on regional cerebral blood flow in neurologically normal subjects. Stroke 14 (1983) 720-724
29. Levin E.D., and Rezvani A.H. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem. Pharmacol. 74 (2007) 1182-1191
30. Levin J.M., Frederick Bde B., Ross M.H., Fox J.F., von Rosenberg H.L., Kaufman M.J., Lange N., Mendelson J.H., Cohen B.M., and Renshaw P.F. Influence of baseline hematocrit and hemodilution on BOLD fMRI activation. Magn. Reson. Imaging 19 (2001) 1055-1062
31. Lucas-Meunier E., Fossier P., Baux G., and Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch. 446 (2003) 17-29
32. Maldjian J.A., Laurienti P.J., Kraft R.A., and Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19 (2003) 1233-1239
33. Manoach D.S., Halpern E.F., Kramer T.S., Chang Y., Goff D.C., Rauch S.L., Kennedy D.N., and Gollub R.L. Test-retest reliability of a functional MRI working memory paradigm in normal and schizophrenic subjects. Am. J. Psychiatry 158 (2001) 955-958
34. Martin L.F., and Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int. Rev. Neurobiol. 78 (2007) 225-246
35. McGill Jr. H.C., McMahan C.A., Malcom G.T., Oalmann M.C., and Strong J.P. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 95-106
36. Miezin F.M., Maccotta L., Ollinger J.M., Petersen S.E., and Buckner R.L. Characterizing the hemodynamic response: effects of presentation rate, sampling procedure, and the possibility of ordering brain activity based on relative timing. Neuroimage 11 (2000) 735-759
37. Muller J.L., Roder C.H., Schuierer G., and Klein H. Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 421-426
38. Murata Y., Sakatani K., Hoshino T., Fujiwara N., Kano T., Nakamura S., and Katayama Y. Effects of cerebral ischemia on evoked cerebral blood oxygenation responses and BOLD contrast functional MRI in stroke patients. Stroke 37 (2006) 2514-2520
39. Ogawa S., Menon R.S., Tank D.W., Kim S.G., Merkle H., Ellermann J.M., and Ugurbil K. Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys. J. 64 (1993) 803-812
40. Pineiro R., Pendlebury S., Johansen-Berg H., and Matthews P.M. Altered hemodynamic responses in patients after subcortical stroke measured by functional MRI. Stroke 33 (2002) 103-109
41. Rogers R.L., Meyer J.S., Shaw T.G., Mortel K.F., Hardenberg J.P., and Zaid R.R. Cigarette smoking decreases cerebral blood flow suggesting increased risk for stroke. Jama 250 (1983) 2796-2800
42. Rogers R.L., Meyer J.S., Shaw T.G., Mortel K.F., and Thornby J. The effects of chronic cigarette smoking on cerebrovascular responsiveness to 5 per cent CO2 and 100 per cent O2 inhalation. J. Am. Geriatr. Soc. 32 (1984) 415-420
43. Salmeron B.J., and Stein E.A. Pharmacological applications of magnetic resonance imaging. Psychopharmacol. Bull. 36 (2002) 102-129
44. Simosky J.K., Stevens K.E., and Freedman R. Nicotinic agonists and psychosis. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 149-162
45. Snitz B.E., MacDonald III A., Cohen J.D., Cho R.Y., Becker T., and Carter C.S. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am. J. Psychiatry 162 (2005) 2322-2329
46. Tost H., Ende G., Ruf M., Henn F.A., and Meyer-Lindenberg A. Functional imaging research in schizophrenia. Int. Rev. Neurobiol. 67 (2005) 95-118
47. Whisnant J.P., Homer D., Ingall T.J., Baker Jr. H.L., O'Fallon W.M., and Wievers D.O. Duration of cigarette smoking is the strongest predictor of severe extracranial carotid artery atherosclerosis. Stroke 21 (1990) 707-714
48. Wiesmann F., Petersen S.E., Leeson P.M., Francis J.M., Robson M.D., Wang Q., Choudhury R., Channon K.M., and Neubauer S. Global impairment of brachial, carotid, and aortic vascular function in young smokers: direct quantification by high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 44 (2004) 2056-2064
49. Worsley K.J., Liao C.H., Aston J., Petre V., Duncan G.H., Morales F., and Evans A.C. A general statistical analysis for fMRI data. Neuroimage 15 (2002) 1-15